Principia buys 49% stake in Rigenerand for €8.7m

The fresh capital will allow the company to implement its database and further develop its technology.

Venture capital vehicle Principia III-Health launched in December 2014 with a €450m target. To date, the vehicle has raised €185m, according to unquote" data. Prior to the transaction, the fund had invested in biotech developer Comecer, neuromodulation provider Wise and protein-based treatment developer Silk biomaterials.

Company
Rigenerand was founded in 2009 and is headquartered in Modena, Italy. The company develops anti-tumour therapies based on stem cells and a technological platform that assists and facilitates stem-cell treatments for the regenerative medicine sector.

People
Principia – Andrea Lenzi (chair); Antonio Falcone (CEO).
Rigenerand – Gianni Bellini (founder, chair); Massimo Dominici (founder, vice chair).

Adviser
Equity – King Wood & Mallesons (legal).
Company – PwC (corporate finance); Avv Luigi Malchiodi (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Italy
• Principia